Table 1.
Subject characteristics by week 24 or week 72 virological response.
| Characteristic | Week 24 virological response
|
Week 72 virological responsea
|
||||
|---|---|---|---|---|---|---|
| No response n = 76 |
Response n = 32 |
P value | No response n = 73 |
Response n = 20 |
P value | |
| Treatment | ||||||
| IFN | 45 (85%) | 8 (15%) | 0.002 | 43 (88%) | 6 (12%) | 0.025 |
| PEG-IFN | 31 (56%) | 24 (44%) | 30 (68%) | 14 (32%) | ||
| Gender | ||||||
| Male | 60 (67%) | 30 (33%) | 0.088 | 60 (77%) | 18 (23%) | 0.511 |
| Female | 16 (89%) | 2 (11%) | 13 (87%) | 2 (13%) | ||
| Race | ||||||
| White, non-Hispanic | 32 (59%) | 22 (41%) | 0.050 | 32 (68%) | 15 (32%) | 0.060 |
| Black, non-Hispanic | 29 (81%) | 7 (19%) | 27 (90%) | 3 (10%) | ||
| Other | 15 (83%) | 3 (17%) | 14 (88%) | 2 (13%) | ||
| Age (years) | ||||||
| 13–39 | 12 (55%) | 10 (45%) | 0.207 | 11 (58%) | 8 (42%) | 0.055 |
| 40–49 | 45 (74%) | 16 (26%) | 45 (85%) | 8 (15%) | ||
| > 50 | 19 (76%) | 6 (24%) | 17 (81%) | 4 (19%) | ||
| Injection drug use history | ||||||
| Never | 22 (56%) | 17 (44%) | 0.027 | 26 (67%) | 13 (33%) | 0.023 |
| Previous use | 54 (78%) | 15 (22%) | 47 (87%) | 7 (13%) | ||
| CD4 cell count (cells/μl) | ||||||
| 100–299 | 18 (82%) | 4 (18%) | 0.274 | 18 (90%) | 2 (10%) | 0.353 |
| 300–500 | 23 (62%) | 14 (38%) | 23 (72%) | 9 (28%) | ||
| > 500 | 35 (71%) | 14 (29%) | 32 (78%) | 9 (22%) | ||
| Antiretroviral regimen | ||||||
| None; missing | 8 (62%) | 5 (38%) | 0.088 | 9 (75%) | 3 (25%) | 0.158 |
| antiretroviral + protease inhibitor | 46 (79%) | 12 (21%) | 43 (86%) | 7 (14%) | ||
| antiretroviral, no protease inhibitor | 22 (59%) | 15 (41%) | 21 (68%) | 10 (32%) | ||
| HIV RNA load | ||||||
| Undetectable | 45 (70%) | 19 (30%) | 1.000 | 45 (83%) | 9 (17%) | 0.208 |
| Detectable | 31 (70%) | 13 (30%) | 28 (72%) | 11 (28%) | ||
| HCV genotype | ||||||
| Genotype 1 | 66 (78%) | 19 (22) | 0.004 | 64 (88%) | 9 (12%) | 0.0002 |
| Genotype non-1 | 10 (43%) | 13 (57%) | 9 (45%) | 11 (55%) | ||
| Log10 (HCV RNA) IU/ml (median value at baseline) | 6.29 | 6.23 | 0.185 | 6.28 | 6.22 | 0.387 |
| Liver histology HAI A–D (inflammation) at baseline | ||||||
| Score 0–5 | 42 (71%) | 17 (29%) | 1.000 | 42 (84%) | 8 (16%) | 0.303 |
| Score > 5 | 34 (71%) | 14 (29%) | 31 (74%) | 11 (26%) | ||
| Missing | 0 (0%) | 1 (100%) | 0 (0%) | 1 (100%) | ||
| Liver histology HAI E (fibrosis) at baseline | ||||||
| Score 0–2 | 41 (66%) | 21 (34%) | 0.204 | 40 (77%) | 12 (23%) | 0.608 |
| Score 3–6 | 35 (78%) | 10 (22%) | 33 (83%) | 7 (18%) | ||
| Missing | 0 (0%) | 1 (100%) | 0 (0%) | 1 (100%) | ||
a
Subjects with week 72 data had baseline and week 24 immunological data available. IFN, interferon alfa-2a; PEG-IFN, pegylated interferon alfa-2a; HCV, hepatitis C virus; HCV, hepatitis C virus; HAI, Histology Acitivity Index.